首页> 外文期刊>Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis >First line and salvage therapy with total therapy 3-based treatment for multiple myeloma-An extended single center experience
【24h】

First line and salvage therapy with total therapy 3-based treatment for multiple myeloma-An extended single center experience

机译:一线和挽救疗法以总疗法3为基础的多发性骨髓瘤治疗-扩展的单中心经验

获取原文
获取原文并翻译 | 示例

摘要

Total therapy 3 is an intensified protocol for multiple myeloma (MM). The "real life" outcomes of this protocol were seldom reported. Data was obtained for 81 patients (newly diagnosed, n = 49; progressive MM, n = 32), most of which had high-risk parameters. Overall response rate following (V) DT-PACE was 96% and 75% for the newly diagnosed and progressive groups, respectively. Median progression-free survival was 42.5 and 9 months, respectively. The 2-year overall survival was 88% and 40%, respectively. Treatment with (V) DT-PACE achieves high response rate among patients with high-risk disease, which can be translated into long-term remission only for newly diagnosed patients. (C) 2014 Elsevier Ltd. All rights reserved.
机译:总疗法3是针对多发性骨髓瘤(MM)的强化治疗方案。很少报道该方案的“现实生活”结果。获得了81例患者的数据(新诊断为49例;进行性MM为32例),其中大多数具有高风险参数。新诊断组和进行性组在(V)DT-PACE后的总缓解率分别为96%和75%。中位无进展生存期分别为42.5和9个月。 2年总生存率分别为88%和40%。 (V)DT-PACE治疗可在高危疾病患者中实现较高的缓解率,仅对于新诊断的患者,可以转化为长期缓解。 (C)2014 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号